Investors Writing for Investors
Results 61 - 70 of 719 : Previous 3 4 5 6 7 8 9 10 11 Next
1 Reason the Street Should Expect Big Things From Pfizer
Don't just ask, "How much inventory?" Ask, "What kind?"
Obama Plan Hits Pharma With Rebates, Pay-to-Delay Ban
President Obama's deficit-cutting plan hits pharma with a one-two-three punch.
Hidden Stocks for High Returns
These underrated stocks could be tomorrow's big winners.
Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry?
The company looks to get in tune with social media.
Is ViroPharma Going to Burn You?
Look here for a clue.
The Motley Fool's Weekly Editors' Picks
Three of the week's most educating, amusing, and enriching articles.
5 Stocks to Beat the Permabull
Be careful following along with someone who is always bullish on the stock market.
Better Late Than Never? Maybe.
Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
And with it go AstraZeneca's hopes of differentiation in a generic world.
AstraZeneca's Crestor Fails to Best Lipitor in Study
Lipitor goes off patent later this year.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK